Atara Biotherapeutics, Inc. financial data

Symbol
ATRA on Nasdaq
Location
2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 70.8 % -78.7%
Quick Ratio 9.29 %
Debt-to-equity -277 % -218%
Return On Equity 202 %
Return On Assets -114 % -20.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.92M shares -95.1%
Common Stock, Shares, Outstanding 4.9M shares -95.1%
Entity Public Float 162M USD -77.4%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 6.14M shares +46.1%
Weighted Average Number of Shares Outstanding, Diluted 6.14M shares +46.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 185M USD -26.2%
General and Administrative Expense 43.7M USD -26.4%
Costs and Expenses 241M USD -35.2%
Operating Income (Loss) -179M USD +41.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -181M USD +40.5%
Income Tax Expense (Benefit) 16K USD -54.3%
Net Income (Loss) Attributable to Parent -181M USD +40.6%
Earnings Per Share, Basic 11.7 USD/shares +81.7%
Earnings Per Share, Diluted 11.7 USD/shares +81.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 31.3M USD -31.8%
Accounts Receivable, after Allowance for Credit Loss, Current 2.42M USD +378%
Inventory, Net 18.7M USD +139%
Other Assets, Current 5.8M USD -42.9%
Assets, Current 62.4M USD -63.8%
Property, Plant and Equipment, Net 2.32M USD -56.7%
Operating Lease, Right-of-Use Asset 48.9M USD -21.3%
Other Assets, Noncurrent 3.61M USD -45.1%
Assets 117M USD -52.4%
Accounts Payable, Current 5.25M USD +26.9%
Employee-related Liabilities, Current 7.27M USD -42.1%
Accrued Liabilities, Current 11.2M USD +5.08%
Contract with Customer, Liability, Current 77.8M USD
Liabilities, Current 148M USD +98.9%
Contract with Customer, Liability, Noncurrent 567K USD -99.3%
Operating Lease, Liability, Noncurrent 38.7M USD -25.2%
Other Liabilities, Noncurrent 4.17M USD -17%
Liabilities 228M USD -4.53%
Accumulated Other Comprehensive Income (Loss), Net of Tax -14K USD +98.5%
Retained Earnings (Accumulated Deficit) -2.02B USD -9.85%
Stockholders' Equity Attributable to Parent -111M USD -1587%
Liabilities and Equity 117M USD -52.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -29.6M USD +22.9%
Net Cash Provided by (Used in) Financing Activities 24.1M USD +10173%
Net Cash Provided by (Used in) Investing Activities 14.7M USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 4.9M shares -95.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 31.5M USD -31.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 114K USD +1.79%
Deferred Tax Assets, Valuation Allowance 475M USD +12.4%
Deferred Tax Assets, Gross 487M USD +11.2%
Operating Lease, Liability 57M USD -19.6%
Depreciation 3.5M USD -2.78%
Payments to Acquire Property, Plant, and Equipment 127K USD -68.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -180M USD +40.5%
Lessee, Operating Lease, Liability, to be Paid 74.5M USD -19.9%
Property, Plant and Equipment, Gross 19.7M USD +0.99%
Operating Lease, Liability, Current 13M USD +7.68%
Lessee, Operating Lease, Liability, to be Paid, Year Two 18.5M USD +2.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 17.2M USD -10.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure +20.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 17.5M USD -20.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 17.3M USD -3.41%
Deferred Tax Assets, Operating Loss Carryforwards 324M USD +6.94%
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 160M USD +6.21%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.76M USD -65.2%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 11.6M USD -23.7%
Share-based Payment Arrangement, Expense 35.8M USD -28%
Interest Expense 4.99M USD +68.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares